The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Open accessAbstract
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental adverse effects may contraindicate the use of anti-inflammatory agents. OBJECTIVE: To systematically review the antidepressant and possible adverse effects of anti-inflammatory interventions. DATA SOURCES: Trials published prior to December, 31, 2013, were identified searching Cochrane Central Register of Controlled Trials, PubMed, EMBASE, PsychINFO, Clinicaltrials.gov, and relevant review articles. STUDY SELECTION: Randomized placebo-controlled trials assessing the efficacy and adverse effects of pharmacologic anti-inflammatory treatment in adults with depressive symptoms, including those who fulfilled the criteria for depression. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Pooled standard mean difference (SMD) and odds ratios (ORs) were calculated. MAIN OUTCOMES AND MEASURES: Depression scores after treatment and adverse effects. RESULTS: Ten publications reporting on 14 trials (6262 participants) were included: 10 trials evaluated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) (n=4,258) and 4 investigated cytokine inhibitors (n=2,004). The pooled effect estimate suggested that anti-inflammatory treatment reduced depressive symptoms (SMD, -0.34; 95% CI, -0.57 to -0.11; I2=90%) compared with placebo. This effect was observed in studies including patients with depression (SMD, -0.54; 95% CI, -1.08 to -0.01; I2=68%) and depressive symptoms (SMD, -0.27; 95% CI, -0.53 to -0.01; I2=68%). The heterogeneity of the studies was not explained by differences in inclusion of clinical depression vs depressive symptoms or use of NSAIDs vs cytokine inhibitors. Subanalyses emphasized the antidepressant properties of the selective cyclooxygenase 2 inhibitor celecoxib (SMD, -0.29; 95% CI, -0.49 to -0.08; I2=73%) on remission (OR, 7.89; 95% CI, 2.94 to 21.17; I2=0%) and response (OR, 6.59; 95% CI, 2.24 to 19.42; I2=0%). Among the 6 studies reporting on adverse effects, we found no evidence of an increased number of gastrointestinal or cardiovascular events after 6 weeks or infections after 12 weeks of anti-inflammatory treatment compared with placebo. All trials were associated with a high risk of bias owing to potentially compromised internal validity. CONCLUSIONS AND RELEVANCE: Our analysis suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms without increased risks of adverse effects. However, a high risk of bias and high heterogeneity made the mean estimate uncertain. This study supports a proof-of-concept concerning the use of anti-inflammatory treatment in depression. Identification of subgroups that could benefit from such treatment might be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients who receive cytokine treatments such as IL-2 or IFN γ as part of their treatment for hepatitis or cancer often develop depressive symptoms 82”
From Major depressive disorder (2016) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Kohler and colleagues found that patients prescribed celecoxib compared to placebo were 7 times more likely to respond to an antidepressant with no increased risks of GI or CV effects (155).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“blockade of cytokines, such as TNF, or of inflammatory signalling pathway components, such as cyclooxygenase 2, has been shown to reduce depressive symptoms in patients with medical illnesses, including rheumatoid arthritis, psoriasis and cancer, as well as in patients with major depressive disorder27–29.”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, it appears that anti-inflammatory agents may only demonstrate effective antidepressant activity in subgroups of patients who show evidence of increased peripheral inflammation, for example individuals with medical conditions including osteoarthritis and psoriasis that are characterized by increased levels of peripheral inflammation and patients with depression with increased”
From The role of inflammation in depression: from evolutionary imperative to modern treatment target (2016) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“depressive symptoms are more frequent in patients with conditions involving inflammation (e.g., autoimmune diseases) and can be reversed through the use of anti-inflammatory drugs (Kojima et al., 2009; Köhler et al., 2014).”
From The interplay between stress, inflammation, and emotional attention: relevance for depression (2019) · cites this paper as Köhler et al., 2014
In the citing paper
“There is also meta-analytic evidence that anti-inflammatory treatments can be effective means for treating depression (Köhler et al., 2014).”
From The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. (2018) · cites this paper as Köhler et al., 2014
In the citing paper
“A meta-analysis of nonsteroidal anti-inflammatory drugs and cytokine inhibitors suggests that anti-inflammatory treatment, in particular celecoxib, decreases depressive symptoms in individuals with major depression or with clinically significant depressive symptoms198.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [198]
In the citing paper
“There is particular interest in how inflammatory cell types in the brain cause depressive symptoms, as anti-inflammatory treatments reduce depressive symptoms in humans [173] and chronic stress enhances inflammation in animal models [174].”
From The molecular and cellular mechanisms of depression: a focus on reward circuitry (2019) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing Risk of Bias in Included Studies
Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch8 · Cited by 3,396
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Gluud, L. L., Villumsen, J., & Gluud, C. N. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,266
The case of the misleading funnel plot
Lau, J., Ioannidis, J. P. A., Terrin, N., Schmid, C. H., & Olkin, I. (2006) · BMJ · doi:10.1136/bmj.333.7568.597 · Cited by 1,766
Flagged first, then by citations
Research works printed but not linked: 2
- [24]24. Raison C, Rutherford RE, Woolwine B, et al. The tumor necrosis factor-alpha antagonist infliximab reduces depressive symptoms in patients with treatment resistant depression and high inflammation. Brain Behav Immun. 2012;26(suppl 1):S49. doi:10.1016/j.bbi.2012.07.200.W. · DOI
- [27]27. Hashemian F, Majd M, Hosseini SM, Sharifi A, Panahi MVS, Bigdeli O. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183-S184.
Cited by
Sorted by citations
Items 201–300 of 942
Biomarkers for Depression: Recent Insights, Current Challenges and Future Prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.16206 · Cited by 76
Fabrazzo, M., Cipolla, S., Signoriello, S., Camerlengo, A., Calabrese, G., Giordano, G. M., Argenziano, G., & Galderisi, S. (2021) · European Psychiatry · doi:10.1192/j.eurpsy.2021.2249 · Cited by 81
Targeting inflammation: a potential approach for the treatment of depression
Bhatt, S., Devadoss, T., Jha, N. K., Baidya, M., Gupta, G., Chellappan, D. K., Singh, S. K., & Dua, K. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01095-1 · Cited by 83
Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis
Pastis, I., Santos, M. G., & Paruchuri, A. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282242 · Cited by 88
Dey, A., & Hankey Giblin, P. A. (2018) · Pharmaceuticals · doi:10.3390/ph11030064 · Cited by 80
Knight, J. M., Costanzo, E. S., Singh, S., Yin, Z., Szabó, A., Pawar, D. S., Hillard, C. J., Rizzo, J. D., D’Souza, A., Pasquini, M. C., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01164-y · Cited by 79
Sarno, E., Moeser, A. J., & Robison, A. J. (2021) · Advances in pharmacology · doi:10.1016/bs.apha.2021.03.004 · Cited by 84
The Impact of Obesity on Microglial Function: Immune, Metabolic and Endocrine Perspectives
Alexaki, V. I. (2021) · Cells · doi:10.3390/cells10071584 · Cited by 84
New drug candidates for depression – a nationwide population‐based study
Kessing, L. V., Rytgaard, H. C. W., Gerds, T. A., Berk, M., Ekstrøm, C. T., & Andersen, P. K. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12957 · Cited by 73
Debnath, M., Berk, M., & Maes, M. H. J. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110343 · Cited by 77
Swardfager, W., Hennebelle, M., Yu, D., Hammock, B. D., LEVITT, A. J., Hashimoto, K., & Taha, A. Y. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.01.010 · Cited by 78
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 76
Rahimian, R., Belliveau, C., Chen, R., & Mechawar, N. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.871997 · Cited by 77
Wang, Y., Xu, J., Liu, Y., Li, Z., & Li, X. (2018) · Neural Plasticity · doi:10.1155/2018/7254016 · Cited by 71
Role of Somatostatin in the Regulation of Central and Peripheral Factors of Satiety and Obesity
Kumar, U., & Singh, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072568 · Cited by 73
Old Friends, immunoregulation, and stress resilience
Langgartner, D., Lowry, C. A., & Reber, S. O. (2018) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2228-7 · Cited by 76
The Role of Anxious Distress in Immune Dysregulation in Patients with Major Depressive Disorder
Gaspersz, R., Lamers, F., Wittenberg, G., Beekman, A. T. F., van Hemert, A. M., Schoevers, R. A., & Penninx, B. W. J. H. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0016-3 · Cited by 71
Herder, C., SCHMITT, A. J., Budden, F., Reimer, A., Kulzer, B., Roden, M., Haak, T., & Hermanns, N. (2017) · Translational Psychiatry · doi:10.1038/s41398-017-0009-2 · Cited by 72
Neuroinflammation in HIV-associated depression: evidence and future perspectives
Rakshasa-Loots, A. M., Whalley, H. C., Vera, J. H., & Cox, S. R. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01619-2 · Cited by 77
Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment
Schmidt, F. M., Kirkby, K. C., & Lichtblau, N. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160115130414 · Cited by 75
Kimura, L. F., Novaes, L. S., Picolo, G., Munhoz, C. D., Cheung, C. W., & Camarini, R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15584 · Cited by 74
Recourt, K., de Boer, P., van der Ark, P. D., Beneš, H., van Gerven, J., Ceusters, M., Nueten, L. V., Drevets, W. C., Bhatacharya, A., Browning, M. D., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02557-5 · Cited by 72
Kanchanatawan, B., Tangwongchai, S., Sughondhabhirom, A., Suppapitiporn, S., Hemrunrojn, S., Carvalho, A. F., & Maes, M. H. J. (2018) · Neurotoxicity Research · doi:10.1007/s12640-017-9860-4 · Cited by 71
Huang, M., Su, S., Goldberg, J. H., Miller, A. H., Levantsevych, O. M., Shallenberger, L. H., Pimple, P. M., Pearce, B. D., Bremner, J. D., & Vaccarino, V. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.10.007 · Cited by 66
Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?
Boorman, E., Zajkowska, Z., Ahmed, R., Pariante, C. M., & Zunszain, P. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4105-9 · Cited by 68
Zuelli, F. M. D. G. C., Brognara, F., Quirino, G. F. S., Hiroki, C. H., Fais, R. S., Del‐Ben, C. M., Ulloa, L., Salgado, H. C., Kanashiro, A., & Loureiro, C. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00618 · Cited by 73
Ghazizadeh‐Hashemi, M., Ghajar, A., Shalbafan, M., Ghazizadeh‐Hashemi, F., Afarideh, M., Malekpour, F., Ghaleiha, A., Ardebili, M. E., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.057 · Cited by 67
Estes, S. J., Huisingh, C., Chiuve, S. E., Petruski‐Ivleva, N., & Missmer, S. A. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa249 · Cited by 67
Zuo, C., Cao, H., Feng, F., Guo, L., Huang, Y., Zhu, L., Gu, Z., Yang, Y., Chen, J., Jiang, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108788 · Cited by 66
Immune cell composition in unipolar depression: a comprehensive systematic review and meta-analysis
Sørensen, N. V., Frandsen, B. H., Orlovska‐Waast, S., Buus, T. B., Ødum, N., Christensen, R. H. B., & Benros, M. E. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01905-z · Cited by 66
Self-citationSickness behaviour and depression: An updated model of peripheral-central immunity interactions
Turkheimer, F., Veronese, M., Mondelli, V., Cash, D., & Pariante, C. M. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.03.031 · Cited by 69
Chang, J., Jiang, T., Shan, X., Zhang, M., Li, Y. Y., Qi, X., Bian, Y., & Zhao, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110931 · Cited by 72
Xie, Z., Huang, J., Sun, G., He, S., Luo, Z., Zhang, L., Li, L., Yao, M., Du, C., Yu, W., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115804 · Cited by 68
Fourrier, C., Sampson, E., Mills, N. T., & Baune, B. T. (2018) · Trials · doi:10.1186/s13063-018-2829-7 · Cited by 66
Targeting the immune system in the treatment of bipolar disorder
Rosenblat, J. D. (2019) · Psychopharmacology · doi:10.1007/s00213-019-5175-x · Cited by 64
Animal models of post-traumatic stress disorder and novel treatment targets
Aspesi, D., & Pinna, G. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000467 · Cited by 67
Flux, M. C., & Lowry, C. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104578 · Cited by 70
Köhler‐Forsberg, O., Petersen, L. V., Mors, O. N., & Gasse, C. (2015) · Brain and Behavior · doi:10.1002/brb3.338 · Cited by 63
Self-citationLi, X., Huan, J.-M., Lin, L., & Hu, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1097196 · Cited by 66
Brain-immune crosstalk in the treatment of major depressive disorder
Branchi, I., Poggini, S., Capuron, L., Benedetti, F., Poletti, S., Tamouza, R., Drexhage, H. A., Penninx, B. W. J. H., & Pariante, C. M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.016 · Cited by 66
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.092 · Cited by 62
Considering future pharmacotherapy for PTSD
Friedman, M. J., & Bernardy, N. C. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.048 · Cited by 62
Lee, Y. L., Subramaniapillai, M., Brietzke, E. M., Mansur, R. B., Ho, R., Yim, S. J., & McIntyre, R. S. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318791944 · Cited by 68
Psiconeuroinmunología de los trastornos mentales
Soria, V., Uribe, J., Salvat‐Pujol, N., Palao, D. J., Menchón, J. M., & Labad, J. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.07.006 · Cited by 68
Holtdirk, F., Mehnert, A., Weiss, M., Mayer, J., Meyer, B., Bröde, P., Claus, M., & Watzl, C. (2021) · PLOS ONE · doi:10.1371/journal.pone.0251276 · Cited by 62
Ferulic acid: An extraordinarily neuroprotective phenolic acid with anti-depressive properties
Dong, X., & Huang, R. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154355 · Cited by 63
Zhu, T., Wang, H., Gu, H., Ju, L.-S., Wu, X., Pan, W., Zhao, M., Yang, J., & Liu, P.-M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01807-4 · Cited by 65
Peterson, C. T., Bauer, S. M., Chopra, D., Mills, P. J., & Maturi, R. K. (2017) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587217730934 · Cited by 68
Plasma and cerebrospinal fluid inflammatory cytokines in perinatal depression
Miller, E. S., Sakowicz, A., Roy, A., Yang, A., Sullivan, J. T., Grobman, W. A., & Wisner, K. L. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.12.015 · Cited by 62
Schrepf, A., Lutgendorf, S. K., & Pyter, L. M. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.04.010 · Cited by 62
Neuroimmune and Inflammatory Signals in Complex Disorders of the Central Nervous System
Liberman, A. C., Trías, E., Chagas, L. D. S., Trindade, P., Pereira, M. D. S., Refojo, D., Hedin‐Pereira, C., & Serfaty, C. A. (2018) · NeuroImmunoModulation · doi:10.1159/000494761 · Cited by 62
Fischer, C. W., Eskelund, A., Budac, D. P., Tillmann, S., Liebenberg, N., Elfving, B., & Wegener, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.015 · Cited by 59
Cytokine variations and mood disorders: influence of social stressors and social support
Audet, M., McQuaid, R. J., Merali, Z., & Anisman, H. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00416 · Cited by 60
Drug repositioning: current approaches and their implications in the precision medicine era
Talevi, A. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1424535 · Cited by 60
Immune dysregulation in depression: Evidence from genome-wide association
Tubbs, J. D., Ding, J., Baum, L., & Sham, P. C. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100108 · Cited by 59
Roles of multiple lipid mediators in stress and depression
Furuyashiki, T., Akiyama, S., & Kitaoka, S. (2019) · International Immunology · doi:10.1093/intimm/dxz023 · Cited by 59
Targeting NLRP3 Inflammasome in Translational Treatment of Nervous System Diseases: An Update
Yu, Q., Zhao, T., Liu, M., Cao, D., Li, J., Li, Y., Xia, M., Wang, X., Zheng, T., Liu, C., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.707696 · Cited by 61
Alvarez-Mon, M. A., Gómez-Lahoz, A. M., Orozco, A., Lahera, G., Diaz, D., Ortega, M. A., Albillos, A., Quintero, J., Aubá, E., Monserrat, J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030220 · Cited by 57
Krishnadas, R., Nicol, A., Sassarini, J., Puri, N., Burden, A. D., Leman, J. A., Combet, E., Pimlott, S. L., Hadley, D. M., McInnes, I. B., et al. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.08.005 · Cited by 61
Klyne, D. M., Barbe, M. F., James, G., & Hodges, P. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147299 · Cited by 57
Simon, M. S., Arteaga-Henríquez, G., Algendy, A. F., Siepmann, T., & Illigens, B. M. W. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s385117 · Cited by 60
Choi, J. H., Lee, M. J., Jang, M., Kim, H., Lee, S., Lee, S., Kim, Y. O., & Cho, I. (2017) · Journal of Ginseng Research · doi:10.1016/j.jgr.2017.04.012 · Cited by 56
Bullmore, E. T. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32356-0 · Cited by 56
Immunotherapy for depression: Recent insights and future targets
Bai, Y., Cai, Y., Chang, D., Li, D., Huo, X., & Zhu, T. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108624 · Cited by 56
Brunoni, A. R., Padberg, F., Vieira, É. L. M., Teixeira, A. L., Carvalho, A. F., Lotufo, P. A., Gattaz, W. F., & Benseñor, I. M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.06.003 · Cited by 59
Low on energy? An energy supply-demand perspective on stress and depression
Østergaard, L., Jørgensen, M. B., & Knudsen, G. M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.08.007 · Cited by 53
Robinson, R., Lahti‐Pulkkinen, M., Heinonen, K., Reynolds, R. M., & Räikkönen, K. (2018) · Pediatric Research · doi:10.1038/s41390-018-0173-y · Cited by 55
Li, J., Wang, H., Du, C., Jin, X., Geng, Y., Han, B., Ma, Q., Li, Q., Wang, Q., Guo, Y., et al. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.07.004 · Cited by 54
Inflammation and Depression: A Public Health Perspective
Chu, A. L., Hickman, M., Steel, N., Jones, P. B., Smith, G. D., & Khandaker, G. M. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.04.015 · Cited by 52
Hashimoto’s thyroiditis induces neuroinflammation and emotional alterations in euthyroid mice
Cai, Y., Wang, F., Chen, Z.-X., Li, L., Fan, H., Wu, Z., Ge, J., Hu, W., Wang, Q., & Zhu, D.-F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1341-z · Cited by 56
Putative neuroprotective pharmacotherapies to target the staged progression of mental illness
Robertson, O. D., Coronado, N. G., Sethi, R., Berk, M., & Dodd, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12775 · Cited by 52
Opel, N., Cearns, M., Clark, S. R., Toben, C. G., Grotegerd, D., Heindel, W. L., Kugel, H., Teuber, A., Minnerup, H., Berger, K., et al. (2019) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180208 · Cited by 51
Inflamed brain: Targeting immune changes and inflammation for treatment of depression
Sakamoto, S., Zhu, X., Hasegawa, Y., Karma, S., Obayashi, M., Alway, E., & Kamiya, A. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13286 · Cited by 51
Diniz, B. S., Lin, C., Sibille, E. L., Tseng, G. C., Lotrich, F. E., Aizenstein, H. J., Reynolds, C. F., & Butters, M. A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.006 · Cited by 50
Depression and Inflammation: Disentangling a Clear Yet Complex and Multifaceted Link
Amodeo, G., Trusso, M. A., & Fagiolini, A. M. (2017) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000236 · Cited by 54
Nitric oxide: Antidepressant mechanisms and inflammation
Ghasemi, M. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.04.004 · Cited by 50
Abiri, B., Sarbakhsh, P., & Vafa, M. (2021) · Nutritional Neuroscience · doi:10.1080/1028415x.2021.1945859 · Cited by 50
Wang, R., Cai, Y., Lu, W., Zhang, R., Shao, R., Yau, S., Stubbs, B., McIntyre, R. S., Su, K., Xu, G., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.115005 · Cited by 51
Kong, X., Zhang, Z., Fu, T., Ji, J., Yang, J., & Gu, Z. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.146 · Cited by 55
Munshi, S., Parrilli, V., & Rosenkranz, J. A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112024 · Cited by 55
Parkinson, J. T., Foley, É. M., Jadon, D. R., & Khandaker, G. M. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20970028 · Cited by 52
van Dooren, F. E. P., Pouwer, F., Schalkwijk, C. G., Sep, S. J. S., Stehouwer, C. D. A., Henry, R. M. A., Dagnelie, P. C., Schaper, N. C., Kallen, C., Koster, A., et al. (2016) · Depression and Anxiety · doi:10.1002/da.22527 · Cited by 49
Dattilo, V., Amato, R., Perrotti, N., & Gennarelli, M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00826 · Cited by 49
Maes, M. H. J., Nowak, G., Caso, J. R., Leza, J. C., Song, C., Kubera, M., Klein, H. C., Gałecki, P., Noto, C. D. S., Glaab, E., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9183-5 · Cited by 50
Why are behavioral and immune traits linked?
Lopes, P. C. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2016.09.008 · Cited by 50
IL-6 and TNF-α in unmedicated adults with ADHD: Relationship to cortisol awakening response
Corominas, M., Armario, A., Gloria Palomar, A., Montse Corrales, F., Carrasco, J., Vanesa Richarte, B., Ferrer, R., Casas, M., & Ramos‐Quiroga, J. A. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.02.017 · Cited by 50
Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders
Ghasemi, M., Phillips, C., Fahimi, A., McNerney, M. W., & Salehi, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.002 · Cited by 53
Liu, Y., Mian, M. F., Neufeld, K. M., & Forsythe, P. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.04.014 · Cited by 49
Asslih, S., Damri, O., & Agam, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116138 · Cited by 51
Licofelone, a potent COX/5-LOX inhibitor and a novel option for treatment of neurological disorders
Razavi, S. M., Khayatan, D., Arab, Z. N., Momtaz, S., Zare, K., Jafari, R. M., Dehpour, A. R., & Abdolghaffari, A. H. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106587 · Cited by 48
Kurt, Z., Özdemir, I., & James, A. M. (2022) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2022.107831 · Cited by 49
Depression as a systemic disease
Sotelo, J. L., & Nemeroff, C. B. (2016) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2016.11.002 · Cited by 48
Depression in the medically ill
Rosenblat, J. D., Kurdyak, P. A., Cosci, F., Berk, M., Maes, M. H. J., Brunoni, A. R., Li, M., Rodin, G., McIntyre, R. S., & Carvalho, A. F. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419888576 · Cited by 47
Kappelmann, N., Rein, M., Fietz, J., Mayberg, H. S., Craighead, W. E., Dunlop, B. W., Nemeroff, C. B., Keller, M. B., Klein, D. N., Arnow, B. A., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01623-9 · Cited by 51
Depression in Poststroke Aphasia
Laures-Gore, J. S., Dotson, V. M., & Belagaje, S. R. (2020) · American Journal of Speech-Language Pathology · doi:10.1044/2020_ajslp-20-00040 · Cited by 47
Baune, B. T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_19 · Cited by 47
Resolution of inflammation and mood disorders
Chistyakov, D. V., Astakhova, A. A., & Sergeeva, M. G. (2018) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2018.08.002 · Cited by 48
Yang, J., Liu, R., Lü, F., Fang, X., Zheng, J., Li, Z., Cui, W., Wang, C., Zhang, J., Xu, S., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00501 · Cited by 46
Squassina, A., Manchia, M., Pisanu, C., Ardau, R., Arzedi, C., Bocchetta, A., Caria, P., Cocco, C., Congiu, D., Cossu, E., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00844-z · Cited by 50
Antidepressant psychopharmacology: is inflammation a future target?
Benedetti, F., Zanardi, R., & Mazza, M. G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000403 · Cited by 45
Metadata
- Authors
- Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J.
- Affiliations
- Research Department P, Aarhus University Hospital, Risskov, Denmark2Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Aarhus University Hospital, Risskov, Denmark
- University of Copenhagen (DK)
- St. George's University (GD)
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2014-12-01
- Volume
- 71
- Issue
- 12
- Pages
- 1381
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2156150528
- Semantic Scholar
- 04c60d39fcaf20a7ee393c91def9fcd0fd3f10fc
- Cited by
- 941
- References
- 56
- Citations by year
- 2026: 48 · 2025: 62 · 2024: 74 · 2023: 81 · 2022: 88 · 2021: 106 · 2020: 94 · 2019: 85 · 2018: 104 · 2017: 85 · 2016: 70 · 2015: 43 · 2014: 1
- FWCI
- 20.40
- Type
- journal article
- Language
- en
- Open access
- green
- pure.au.dk
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Lundbeckfonden (R155-2014-1724)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- anti-inflammatory therapy, depression, depressive symptoms, nonsteroidal anti-inflammatory drugs, cytokine inhibitors, celecoxib, COX-2 inhibitors, antidepressant effects, adverse effects, remission, treatment response, adults with depression
- MeSH terms
- Anti-Inflammatory Agents, Depression, Humans, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
